Hepatocellular carcinoma (HCC) is one of the world's most common and deadly cancers.
Less than one-third of patients can currently benefit from potentially curative therapies in the …

Abstract According to the International Agency for Research on Cancer, approximately
670,000 new cases of hepatocellular carcinoma (HCC) developed in 2005, making it the fifth …

Hepatocellular carcinoma (HCC), once considered an orphan disease in the West, has
become a global health concern. It is the third leading cause of cancer death worldwide, and …

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most lethal
neoplasm, causing an estimated 700000 deaths annually. Currently HCC has only one …

Accumulated understanding of the molecular pathways regulating cancer progression has
led to the development of novel targeted therapies. Hepatocellular carcinoma (HCC) …

Hepatocellular carcinoma (HCC) is an aggressive tumor and the sixth most common form of
cancer worldwide. Surgery is the gold-standard treatment for local disease and often …

Opinion statement Hepatocellular carcinoma (HCC) is one of the most lethal cancers
globally, particularly in certain regions of the world. Although the major risk factors for HCC …

Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with several
genomic alterations. There is evidence of aberrant activation of several signaling cascades …

Hepatocellular carcinoma is the fastest growing cause of cancer related death globally.
Sorafenib, a multi-targeted kinase inhibitor, is the only drug proven to improve outcomes in …

Seven years have passed since sorafenib was approved as a systemic chemotherapeutic
agent that improves survival in patients with advanced hepatocellular carcinoma (HCC) …